/
Dr. Jeffrey Goldberger Dr. Jeffrey Goldberger

Dr. Jeffrey Goldberger - PowerPoint Presentation

stefany-barnette
stefany-barnette . @stefany-barnette
Follow
377 views
Uploaded On 2017-10-14

Dr. Jeffrey Goldberger - PPT Presentation

University of Miami Miller School of Medicine Presented by Dr Daniele Wikoff ToxStrategies 1 Systematic review of the potential adverse effects of caffeine consumption in healthy adults pregnant women adolescents and ID: 595809

effects day cardiovascular confidence day effects confidence cardiovascular caffeine comparator 400 healthy evidence studies blood pressure adverse level change

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Dr. Jeffrey Goldberger" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Dr. Jeffrey GoldbergerUniversity of Miami Miller School of MedicinePresented byDr. Daniele WikoffToxStrategies

1

Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and

children:

Cardiovascular OutcomeSlide2
PECO Questions for the Cardiovascular Outcome

2

For [population], is caffeine intake above [dose], compared to intakes [dose] or less, associated with adverse effects

on cardiovascular health outcomes

?

Example: For healthy adults,

is caffeine intake

above 400 mg/day, compared to intakes 400 mg/day or less, associated with adverse effects on cardiovascular health outcomes?

P

opulation

Healthy

Adults

Healthy

Pregnant

Women

Healthy Adolescents

Healthy

Children

E

xposure

> 400 mg/day

> 300 mg/day

> 2.5 mg/kg-day

> 2.5 mg/kg-day

C

omparator

≤ 400 mg/day

≤ 300 mg/day

≤ 2.5 mg/kg-day

≤ 2.5 mg/kg-day

O

utcome

Adverse cardiovascular effectsSlide3
Characterization of Data for Cardiovascular

OutcomeData TypeCharacterizationNumber of studies

203 included; 73 excluded

Study types

Mostly randomized controlled trials; some observational studies; 5 meta-analyses

Populations

Mostly healthy adults; few children/adolescentsExposurePure caffeine (RCTs) orDietary, e.g., coffee, tea soda, energy drinks etc. (observational studies)Outcome (Endpoints)Clinical:

Mortality (e.g. stroke, coronary heart disease) Morbidity (e.g. acute myocardial infarctions, atrial fibrillation, stroke)Physiological: aortic stiffness, blood pressure, cerebral blood flow, heart rate, heart rate variability, LDL, cholesterol, plasma and urinary constituents, other hemodynamic measurements, ventricular function3Slide4
Mortality

The majority of evidence support that 400 mg caffeine/day in healthy adult populations is an acceptable intake which is not associated with significant concern for cardiovascular mortalityAt higher intakes up to ~855 mg/day, there are no consistently reported effects Several studies, reported findings that are suggestive of protective effects Studies

reporting effects, both above and below the comparator, were conditional (e.g., observed in subset of data evaluated) M

oderate

level of confidence in the body of

evidence

4Slide5
Morbidity

Evidence support that 400 mg caffeine/day in healthy adult populations is an acceptable intake which is not associated with significant concern regarding cardiovascular morbidity Several studies (including meta-analyses) suggested that the comparator is too low All comparison points above 400 mg/day (up to 1050 mg/day) were no effect levelsSome studies, including two meta-analyses reported

effect levels below the comparator Associations were observed only in specific

genotypes (highlighting potential

role of kinetic

influence)

Moderate level of confidence in the evidence baseincreased by the low level of indirectness, low risk of bias in the individual studies 5Slide6

Blood PressureIntakes both below and above the comparator, have the potential to result in an increase in blood pressure (often only a few mmHg) in all populations evaluatedBiological

significance of this small magnitude of change is difficult to interpret (and is conditional) The

range of normal blood pressure variation during the day exceeds the increase that is associated with caffeine

The

blood pressure increase with exercise is typically substantially greater than that observed with

caffeineThe comparator of 400 mg/day in healthy adults is too high if one is only considering the potential for caffeine to cause a physiological change in blood pressure The comparator of 400 mg/day is likely acceptableConsidering the small magnitude of changes in this physiological parameter Lack of information demonstrating an association between chronic caffeine-mediated blood pressure increases relative to known cardiovascular risk factorsModerate level of confidence in this evidence base

6Slide7

Evaluation of Individual Study Quality (Risk of Bias)Overall “probably low” risk of biasLimited by exposure characterization in observational studies (Q8)7

+2

: Definitely low

+1

: Probably low

-1: Probably high-2: Definitely highSlide8
Factors that increased or decreased confidence in the body of evidence by endpoint

8EndpointNo. of Studies

Initial Confidence Rating

Based on study type and study features (OHAT, 2015)

Overall

RoB Domain-based evaluation of risk of bias per the OHAT RoB tool (OHAT, 2015) IndirectnessWas the study designed to evaluate the PECO? Magnitude

Strength of effect (when effect observed below the comparator) ConfoundingWere plausible confounders that would change the observed effect accounted for? Consistency Were findings consistent in demonstrating effects or lack of effects at or below the comparator Final Confidence RatingWhat is the overall rating when factors that increase or decrease confidence were consideredAdults

Mortality

13

Moderate

↑/-

--

↑/-

Moderate

Morbidity

18

Moderate

↑/-

--

Moderate

Blood

pressure

115

Moderate to high

↑/-

↓/-

--ModerateHeart rate53Moderate to high↑/-↑—Cholesterol24Moderate to high↑/-↑/-↓—↑Moderate to highHeart rate viability13Moderate to high↑/-↑--—↑/-Moderate to highAdolescents and childrenBlood pressure10Moderate to high↑/-↑↓—↑HighHeart rate6High↑↑——↑/-High

increased confidence - no

change

to confidence

decreased

confidence Slide9
Developing Conclusions for the Outcome: Integration of Weight of Evidence Considerations

9Slide10
WoE Conclusion: Cardiovascular

Adults: When the weight of evidence was considered, with particular emphasis on level of adversity, 400 mg caffeine/day was found to be an acceptable intake which is not associated with significant concern regarding adverse cardiovascular effects. Some findings suggested that the comparator was too low (clinical endpoints)Some findings reported effects below the comparator (mostly physiological endpoints)Limited by the inability to ascertain the conditions and magnitude of change that would be considered adverse

Moderate to high level of confidence in the evidence base.

Children and adolescents: the

evidence base was insufficient

to develop conclusion

Available data (blood pressure and heart rate) are inconsistent10Slide11
Future Research Needs

More research in children and adolescent populationsBetter understanding of dose-response relationships following chronic exposure for some endpoints (e.g. endothelial function and heart rate variability)In some cases (e.g. certain physiological endpoints), a better characterization of what, if any, magnitude of change may be associated with adverse effects11